Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1

Alnylam Pharmaceuticals has filed an application with the US Food and Drug Administration (FDA) seeking the latter’s approval for lumasiran for the treatment of primary hyperoxaluria type 1 (PH1).